Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Treatment-emergent adverse effects (TEAEs) occurred in 164 patients (67.2%), of which 48 (19.7%) were possibly associated with the study treatment. A total of 18 (7.4%) and 17 (7.0%) patients reported ...

Cosentyx has since been joined by other IL-17 inhibitors including Eli Lilly's Taltz (ixekizumab) and Bausch Health's Siliq/Kyntheum (brodalumab), but UCB is convinced it can make headway in the ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Exposure to tumor necrosis factor inhibitors was associated with a lower risk for incident myocardial infarction or stroke among patients with ankylosing spondylitis. Tumor necrosis factor (TNF ...

THE RELATIONSHIP between biologic therapies and the risk of major adverse cardiovascular events (MACEs) and venous ...

Figure 1. Schematic illustration of NLRP3 inflammasome pathway and potential blockade sites of various pharmacological inhibitors. The signal 1 or the priming signal is mediated by pathogenic PAMPs ...

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...